Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 15, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Repurchased: 2,000,000 Ordinary shares
- Price per Share: 1,246.98 pence
- Treasury Shares Held: 359,262,158 shares (6.34% of total voting rights)
- Shares in Issue: 5,662,948,588 shares (excluding Treasury shares)
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. Following the August 15 transaction, the company's Treasury holdings increased to 359,262,158 shares. The total number of shares in issue remains 5,662,948,588, which serves as the denominator for calculating shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (2,000,000 shares at 1,246.98 pence) against the company's cash position in other filings.
- Confirm the updated share count of 5,662,948,588 for accurate calculation of ownership percentages and voting rights.
- Note that 6.34% of total voting rights are now held in Treasury and do not carry voting rights.
- Check subsequent filings for further repurchase activity under the authority granted on May 23, 2007.